Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

361. Pentoxifylline for neonatal sepsis. (Abstract)

Pentoxifylline for neonatal sepsis. Although the overall incidence of neonatal sepsis has declined over the past decade, mortality remains high in the pre term infant. The high level of mortality and morbidity from sepsis despite the use of potent anti-microbial agents, and the global emergence of antibiotic resistance, have led to the search for new modalities to boost new born host defences. Pentoxifylline, a xanthine derivative and a phosphodiesterase inhibitor, has been shown to possess (...) sepsis in newborn infants less than 28 days old. Eligible trials were required to report treatment effects on at least one of the following outcomes: all cause mortality during initial hospital stay, neurological development at two years of age or later, length of hospital stay, duration of ventilation via endotracheal intubation, chronic lung disease in survivors, periventricular leukomalacia, necrotising enterocolitis, or adverse events.Two reviewers independently abstracted information

2003 Cochrane

362. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. Full Text available with Trip Pro

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex with tissue factor and blood protease factors leading to inhibition of thrombin generation and fibrin formation.To determine if administration of tifacogin (recombinant TFPI) provides mortality (...) benefit in patients with severe sepsis and elevated international normalized ratio (INR) and to assess tifacogin safety in severe sepsis, including patients with low INR.A randomized, double-blind, placebo-controlled, multicenter, phase 3 clinical trial conducted from March 21, 2000, through September 27, 2001, in 245 hospitals in 17 countries in North America, Europe, and Israel.The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2

2003 JAMA Controlled trial quality: predicted high

363. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

364. Evaluation of drotrecogin alpha in adult patients with severe sepsis

Evaluation of drotrecogin alpha in adult patients with severe sepsis Evaluation of drotrecogin alpha in adult patients with severe sepsis Evaluation of drotrecogin alpha in adult patients with severe sepsis Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Evaluation of drotrecogin alpha in adult patients with severe sepsis. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2003 Authors' objectives This study aims to summarise the available evidence on the use of drotrecogin alpha in adult patients with severe sepsis. Authors' conclusions The benefit of drotrecogin alpha was established within the context of state-of-the-art

2003 Health Technology Assessment (HTA) Database.

365. Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert)

Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Swedish Council on Technology Assessment in Health Care Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Swedish Council on Technology Assessment in Health Care. Drotrecogin alfa (Xigris(R)) for severe sepsis - early assessment briefs (Alert) Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2003 Authors' objectives This review aims to assess the available evidence on drotrecogin alfa (Xigris(R)) for severe sepsis. Authors' conclusions Currently there is moderate scientific evidence that show positive effects of drotrecogin alfa on survival in patients with severe sepsis

2003 Health Technology Assessment (HTA) Database.

366. Beyond the complete blood cell count and C-reactive protein: a systematic review of modern diagnostic tests for neonatal sepsis

Beyond the complete blood cell count and C-reactive protein: a systematic review of modern diagnostic tests for neonatal sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

367. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis

Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis Fowler R A, Hill-Popper M, Stasinos J, Petrou C (...) , Sanders G D, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of recombinant human activated protein C (drotrecogin alfa) for patients with severe sepsis who were being treated in an intensive care unit (ICU). Four

2003 NHS Economic Evaluation Database.

368. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany Neilson A R, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was drotrecogin alpha (activated) (DAA) for the treatment of severe sepsis. DAA was given in 5mg vials based on a 12 hourly dosage. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised both the whole

2003 NHS Economic Evaluation Database.

369. Drotrecogin alfa (Xigris®) for severe sepsis</a>

Drotrecogin alfa (Xigris®) for severe sepsis Drotrecogin alfa (Xigris®) for severe sepsis We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Drotrecogin alfa (Xigris®) for severe sepsis Share: Reading time approx. 5 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert Version (...) : 1 Technology and target group Sepsis is a life-threatening condition characterized by a systemic inflammatory response to infection. The condition is classified as severe sepsis if at least one vital organ system ceases to function. Septic shock is diagnosed when low arterial blood pressure that does not resolve with adequate fluid resuscitation occurs. Mortality is approximately 20 percent in cases of severe sepsis and 45 percent in cases of septic shock. Drotrecogin alfa (Xigris®) is a new

2003 Swedish Council on Technology Assessement

370. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2003 PedsCCM Evidence-Based Journal Club

371. Early enteral immunonutrition in patients with severe sepsis: Results of an interim analysis of a randomized multicentre clinical trial.

Early enteral immunonutrition in patients with severe sepsis: Results of an interim analysis of a randomized multicentre clinical trial. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2003 PedsCCM Evidence-Based Journal Club

372. An economic evaluation of activated protein C treatment for severe sepsis. Full Text available with Trip Pro

An economic evaluation of activated protein C treatment for severe sepsis. Recombinant human activated protein C was shown in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study to reduce mortality among patients with severe sepsis. A post hoc reanalysis by the Food and Drug Administration (FDA) of data from this study suggested that the reduction in mortality was restricted to patients with Acute Physiology and Chronic Health Evaluation (APACHE II (...) ) scores of 25 or more.We estimated the cost effectiveness of activated protein C as compared with conventional care for patients with severe sepsis. We performed an economic analysis involving all patients, as well as analyses of subgroups defined according to age and severity of illness. The probabilities of transition between clinical states and the estimates of resource use were derived from a population-based cohort of patients with severe sepsis. We used data on the effectiveness of activated

2002 NEJM

373. Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. Full Text available with Trip Pro

Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. To quantify risk factors for and the prevalence of early onset group B streptococcal sepsis in neonates in a geographically defined population.Cases were collected prospectively for two years from April 1998 and compared with four controls each, matched for time and place of delivery.The former Northern health region of the United Kingdom.Infants infected with group B streptococcus in the first week (...) of life.The prevalence of early onset group B streptococcal sepsis was 0.57 per 1000 live births. Premature infants comprised 38% of all cases and 83% of the deaths. Prematurity (odds ratio 10.4, 95% confidence interval 3.9 to 27.6), rupture of the membranes more than 18 hours before delivery (25.8, 10.2 to 64.8), rupture of the membranes before the onset of labour (11.1, 4.8 to 25.9), and intrapartum fever (10.0, 2.4 to 40.8) were significant risk factors for infection. Had the interim recommendations

2002 BMJ

374. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. (Abstract)

Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. It is uncertain whether the rates and causes of early-onset sepsis (that occurring within 72 hours after birth) among very-low-birth-weight infants have changed in recent years, since antibiotics have begun to be used more widely during labor and delivery.We studied 5447 very-low-birth-weight infants (those weighing between 401 and 1500 g) born at centers of the Neonatal Research Network of the National Institute (...) of Child Health and Human Development between 1998 and 2000 who had at least one blood culture in the first three days of life and compared them with 7606 very-low-birth-weight infants born at centers in the network between 1991 and 1993.Early-onset sepsis (as confirmed by positive blood cultures) was present in 84 infants in the more recent birth cohort (1.5 percent). As compared with the earlier birth cohort, there was a marked reduction in group B streptococcal sepsis (from 5.9 to 1.7 per 1000 live

2002 NEJM

375. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. (Abstract)

Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. Increased intestinal epithelial apoptosis is present in both human autopsy studies and animal models of sepsis. Whether altering gut apoptosis decreases mortality in sepsis induced by pathogenic bacteria outside the gut is unknown.To determine if decreasing levels of intestinal cell death improves survival in a murine model of Pseudomonas aeruginosa pneumonia-induced sepsis.Prospective (...) sepsis. These results suggest that intestinal epithelial apoptosis may play a role in sepsis-related mortality.

2002 JAMA

376. Opebecan for meningococcal sepsis - horizon scanning review

Opebecan for meningococcal sepsis - horizon scanning review Opebecan for meningococcal sepsis - horizon scanning review Opebecan for meningococcal sepsis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Opebecan for meningococcal sepsis - horizon scanning review. Birmingham: National Horizon Scanning (...) Centre (NHSC). New and Emerging Technology Briefing. 2002 Authors' objectives To summarise the current research on opebecan for meningococcal sepsis. Authors' conclusions - Clinical impact: Meningococcal sepsis is associated with significant morbidity and mortality. Should treatment with opebecan prove to be successful for severe septicaemia in children (up to 900 children in England and Wales) it is possible that the patient group may be widened to include both less severe paediatric disease

2002 Health Technology Assessment (HTA) Database.

377. Afelimomab for sepsis - horizon scanning review

Afelimomab for sepsis - horizon scanning review Afelimomab for sepsis - horizon scanning review Afelimomab for sepsis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Afelimomab for sepsis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology (...) Briefing. 2002 Authors' objectives To summarise the available evidence on afelimomab for sepsis. Authors' conclusions - Clinical impact: The clinical impact associated with the introduction of afelimomab initially appears small and needs further assessment when trial results are fully published. However afelimomab is a new treatment for a patient group that has a very high mortality (50-80%) and any benefit may be clinically significant. - Service impact: It is likely that there will be some service

2002 Health Technology Assessment (HTA) Database.

378. Activated protein C for severe sepsis

Activated protein C for severe sepsis Activated protein C for severe sepsis Activated protein C for severe sepsis Garces K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Garces K. Activated protein C for severe sepsis. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation (...) des Technologies de la Sante (CCOHTA) 2002: 4 Authors' objectives To summarise the available evidence on activated protein C for severe sepsis. Authors' conclusions - Severe sepsis is a systemic inflammatory response to infection involving organ dysfunction. Severe sepsis is a common cause of death and is associated with a 20% to 56% mortality rate. - Drotrecogin alpha (activated) is a recombinant human activated protein C (rhAPC) approved in the U.S. for the reduction of mortality in adult

2002 Health Technology Assessment (HTA) Database.

379. An economic evaluation of activated protein C treatment for severe sepsis

An economic evaluation of activated protein C treatment for severe sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 NHS Economic Evaluation Database.

380. An economic evaluation of activated protein C treatment for severe sepsis

An economic evaluation of activated protein C treatment for severe sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2002 PedsCCM Evidence-Based Journal Club